Prof Salvador Macip

My research interest is to understand the mechanisms involved in cancer and ageing in order to design better targeted and personalized therapies for cancer and other age-related diseases.

I completed a medical degree at the University of Barcelona where I also obtained a PhD in Molecular Genetics. After a nine years at Mount Sinai Hospital in New York, I came to the University of Leicester as a New Blood Lecturer in Mechanisms of Cell Death and head of the Mechanisms of Cancer and Ageing Laboratory in 2008.

Get all the updated details about my research here:

http://lab.macip.org/index.htm

Project 1. Precision medicines for B-cell leukaemias

In collaboration with Prof Martin Dyer's lab we are defining novel personalized therapeutic strategies against B-cell malignancies that can be immediately applied in the clinic. For instance we studied the response of a patient with Hairy Cell Leukaemia to BRAF inhibitor vemurafenib both from the clinical perspective and at a cellular and molecular level.

Project 2. Understanding the molecular mechanisms of ageing

Our experiments on senescence (cellular ageing) will allow us to better understand why we age and also will provide the basis for new treatments that could be applied to slow down and improve ageing. We have already identified novel markers of senescence that could be used to detect senescent cells in vivo and in vitro.

Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. S Macip, M Igarashi, L Fang, A Chen, ZQ Pan, SW Lee, SA Aaronson. The EMBO journal 21 (9), 2180-2188 352 2002

Influence of induced reactive oxygen species in p53-mediated cell fate decisions. S Macip, M Igarashi, P Berggren, J Yu, SW Lee, SA Aaronson. Molecular and cellular biology 23 (23), 8576-8585 341 2003

ASC is a Bax adaptor and regulates the p53-Bax mitochondrial apoptosis pathway. T Ohtsuka, H Ryu, YA Minamishima, S Macip, J Sagara, KI Nakayama. Nature cell biology 6 (2), 121-128 252 2004

HB-EGF is a potent inducer of tumor growth and angiogenesis. PP Ongusaha, JC Kwak, AJ Zwible, S Macip, S Higashiyama, N Taniguchi. Cancer research 64 (15), 5283-5290 222 2004

Transcriptional role of p53 in interferon-mediated antiviral immunity. C Muñoz-Fontela, S Macip, L Martínez-Sobrido, L Brown, J Ashour. The Journal of experimental medicine 205 (8), 1929-1938 197 2008

Characterization of novel markers of senescence and their prognostic potential in cancer. M Althubiti, L Lezina, S Carrera, R Jukes-Jones, SM Giblett, A Antonov. Cell death & disease 5 (11), e1528-e1528 137 2014

Reactive oxygen species and mitochondrial sensitivity to oxidative stress determine induction of cancer cell death by p21. I Masgras, S Carrera, PJ De Verdier, P Brennan, A Majid, W Makhtar., Journal of Biological Chemistry 287 (13), 9845-9854 92 2012

Loss of polycystin-1 causes centrosome amplification and genomic instability. L Battini, S Macip, E Fedorova, S Dikman, S Somlo, C Montagna. Human molecular genetics 17 (18), 2819-2833 86 2008

Efficacy of vemurafenib in hairy-cell leukemia. J Samuel, S Macip, MJS Dyer. New England Journal of Medicine 370 (3), 286-288 57 2014

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. HS Walter, S Jayne, SA Rule, G Cartron, F Morschhauser, S Macip. Blood, The Journal of the American Society of Hematology 129 (20), 2808-2810 46 2017

Oxidative stress induces a prolonged but reversible arrest in p53-null cancer cells, involving a Chk1-dependent G 2 checkpoint. S Macip, A Kosoy, SW Lee, MJ O'Connell, SA Aaronson. Oncogene 25 (45), 6037-6047 41 2006

BTK modulates p53 activity to enhance apoptotic and senescent responses. M Althubiti, M Rada, J Samuel, JM Escorsa, H Najeeb, KG Lee, KP Lam. Cancer research 76 (18), 5405-5414

Biological mechanisms of ageing, biomarkers of ageing and anti-ageing strategies

Pathways of resistance and relapse in B cell malignancies

BS3003 (module convenor)

MB3001

and others